Trials / Unknown
UnknownNCT05866172
HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC
A Randomized Controlled Study of Hepatic Arterial Infusion Chemotherapy of FOLFOX With or Without Zoledronic Acid for the Prevention of Bone Metastases in Advanced Hepatocellular Carcinoma Staged at BCLC C
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 264 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Zoledronic acid was initially used for bone metastases in various malignancies. However, it is unknown whether hepatic arterial infusion chemotherapy combined with zoledronic acid can improve overall survival of unresectable hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | HAIC | hepatic arterial infusion of oxaliplatin, LV and 5-fu (20h) |
| DRUG | Zoledronic acid | Zoledronic acid 4mg iv.drip |
Timeline
- Start date
- 2023-05-10
- Primary completion
- 2024-12-01
- Completion
- 2025-06-01
- First posted
- 2023-05-19
- Last updated
- 2023-05-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05866172. Inclusion in this directory is not an endorsement.